 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- | Journal: Pulchinenoside B4 alleviates DSS-induced colitis by inhibiting CD1d-dependent NLRP3 inflammasome activation in macrophages. (Pubmed Central) - Feb 11, 2025
Macrophage-specific CD1d loss has been shown to reverse the protective effects of PB4. These findings have paved the way for the development of CD1d/NLRP3-based novel anti-colitis agents and will facilitate the future clinical translation of the plant-derived drug PB4.